antibody elimination
Recently Published Documents


TOTAL DOCUMENTS

9
(FIVE YEARS 1)

H-INDEX

5
(FIVE YEARS 0)

2021 ◽  
Vol 22 (11) ◽  
pp. 6051
Author(s):  
Gilles Thibault ◽  
Gilles Paintaud ◽  
Hsueh Cheng Sung ◽  
Laurie Lajoie ◽  
Edouard Louis ◽  
...  

The FcγRIIA/CD32A is mainly expressed on platelets, myeloid and several endothelial cells. Its affinity is considered insufficient for allowing significant binding of monomeric IgG, while its H131R polymorphism (histidine > arginine at position 131) influences affinity for multimeric IgG2. Platelet FcγRIIA has been reported to contribute to IgG-containing immune-complexe clearance. Given our finding that platelet FcγRIIA actually binds monomeric IgG, we investigated the role of platelets and FcγRIIA in IgG antibody elimination. We used pharmacokinetics analysis of infliximab (IgG1) in individuals with controlled Crohn’s disease. The influence of platelet count and FcγRIIA polymorphism was quantified by multivariate linear modelling. The infliximab half-life increased with R allele number (13.2, 14.4 and 15.6 days for HH, HR and RR patients, respectively). It decreased with increasing platelet count in R carriers: from ≈20 days (RR) and ≈17 days (HR) at 150 × 109/L, respectively, to ≈13 days (both HR and RR) at 350 × 109/L. Moreover, a flow cytometry assay showed that infliximab and monomeric IgG1 bound efficiently to platelet FcγRIIA H and R allotypes, whereas panitumumab and IgG2 bound poorly to the latter. We propose that infliximab (and presumably any IgG1 antibody) elimination is partly due to an unappreciated mechanism dependent on binding to platelet FcγRIIA, which is probably tuned by its affinity for IgG2.


2007 ◽  
Vol 11 (5) ◽  
pp. 319-324 ◽  
Author(s):  
Naoki Kawagishi ◽  
Ikuo Takeda ◽  
Shigehito Miyagi ◽  
Kazushige Satoh ◽  
Yorihiro Akamatsu ◽  
...  

2002 ◽  
Vol 88 (12) ◽  
pp. 898-899 ◽  
Author(s):  
Ryan Hansen ◽  
Joseph Balthasar

SummaryWe have recently shown that intravenous immunoglobulin (IVIG) therapy leads to an increased rate of anti-platelet antibody clearance in an animal model of immune thrombocytopenia. The present study was performed to confirm the importance of the FcRn receptor in mediating this effect of IVIG. The pharmacokinetics of an anti-platelet antibody, 7E3, were studied in mice lacking expression of FcRn and in control mice, both in the presence and absence of IVIG. IVIG increased the clearance of 7E3 in mice with functioning FcRn receptors, with an average clearance value of 14.4 ± 1.4 ml/d/kg in IVIG treated mice vs. 5.2 ± 0.3 ml/d/kg in controls (P <0.001). In mice lacking expression of FcRn, IVIG treatment did not increase 7E3 clearance (61.0 ± 3.6 ml/d/kg vs. 71.5 ± 4.0 ml/d/kg in controls). Thus, these data support the hypothesis that IVIG increases antibody elimination via saturation of FcRn.


2001 ◽  
Vol 5 (6) ◽  
pp. 449-454 ◽  
Author(s):  
Naoki Kawagishi ◽  
Nobuhiro Ohkohchi ◽  
Keisei Fujimori ◽  
Takashi Orii ◽  
Nozomi Koyamada ◽  
...  

1999 ◽  
Vol 3 (3) ◽  
pp. 268-270 ◽  
Author(s):  
M. Toepfer ◽  
H. Schiffl ◽  
T. Sitter ◽  
D. Pongratz ◽  
W. Müller‐Felber
Keyword(s):  

1990 ◽  
Vol 82 (1) ◽  
pp. 47-50 ◽  
Author(s):  
Cynthia Nourigat ◽  
Christopher C. Badger ◽  
Irwin D. Bernstein

Sign in / Sign up

Export Citation Format

Share Document